US Alzheimer’s Therapeutics Market Analysis

US Alzheimer’s Therapeutics Market Executive Summary

US alzheimer’s therapeutics market valued at $2016 Mn in 2022, projected to reach $3490 Mn by 2030 with a 7.1% CAGR.

Alzheimer's is a neurological disease that affects memory, behavior, and thought processes. Usually, it begins gradually, worsens with time, and impairs an individual's ability to carry out everyday duties. In Alzheimer's disease, aberrant changes in the brain, such as the accumulation of plaques and tangles, cause nerve cells to die. There is presently no treatment for Alzheimer's disease. On the other hand, some medications can improve quality of life and assist manage symptoms. By regulating particular chemicals in the brain, these drugs like donepezil, rivastigmine, and memantine relieve memory and cognitive problems. Furthermore, non-pharmacological strategies like maintaining a healthy lifestyle, participating in social and cognitive activities, and creating a supportive environment may help to enhance overall illness management.

Currently, 6.7 Mn Americans 65 years of age and older suffer from Alzheimer's disease, in the absence of medical advancements, this figure may rise to 13.8 Mn by 2060. In 2022, people with Alzheimer's disease or other dementias received care from about 11 Mn family members and caregivers who were unpaid for almost 18 billion hours. In the same year, the unpaid care given to dementia patients was valued at $339.5 billion. Interestingly, Medicare pays over three times as much per person for individuals 65 and older who have Alzheimer's or other dementias than for those who do not have these disorders, Medicaid pays more than 22 times as much. In 2023, $345 billion has been paid in total for health care, long-term care, and hospice services for people 65 and older who have dementia.

The FDA fully approved Eisai's Leqembi, the first Alzheimer's medication to receive this distinction, marking an important milestone in the fight against the illness. Leqembi has been effective in reducing cognitive loss in people with Alzheimer's disease who are still in the early stages of the illness. It is intended to treat amyloid plaques in the brain, a major feature of the condition. Even with this achievement, concerns remain about possible adverse effects and the drug's high annual cost of $26,500.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Alzheimer's Disease: Estimates suggest that by 2060, there will be 14 Mn Americans living with Alzheimer's disease, highlighting the critical and growing need for effective therapies. Increased life expectancy and an older population are two further factors contributing to the rise in Alzheimer's cases.

Increased Awareness and Early Diagnosis: Growing public awareness of Alzheimer's disease and improved diagnostic tools make it easier to diagnose the disease early and encourage more people to seek treatment. Initiating interventions early with potential disease-modifying therapies extends the timeframe for potential positive outcomes.

Entry of New Disease-Modifying Therapies: With the recent approval of Biogen's Aduhelm and Eisai's Leqembi, along with promising new drugs like Eli Lilly's Donanemab and Genentech's Gantenerumab, there is hope for slowing the progression of the disease and maybe changing the underlying pathology. Unlike current symptomatic treatments, these novel therapeutics address a more comprehensive unmet requirement. The market continues to grow thanks to these breakthroughs in treatment. Such treatment advancements support the market's ongoing expansion. Treatment improvements like these contribute to the market's continued growth.

Market Restraints

High Drug Costs and Affordability Concerns: Currently, the annual expenses for Alzheimer's treatments range from $26,500 to $56,000, inflicting a considerable financial strain on patients. The excessive expenses of these medications provide financial hardship for patients, causing some of them to discontinue their treatment, thereby impeding the market's expansion.

Limited Efficacy and Uncertain Long-Term Benefits: The effectiveness of current drugs, including Leqembi and Aduhelm, in slowing down cognitive deterioration is questionable, and their long-term sustainability is also questionable. Hesitancy is caused by several factors, including the lack of a clear remedy or solid proof that the disease has improved.

Potential Side Effects and Safety Concerns: Safety issues are raised by side effects associated with emerging Alzheimer's treatments, such as brain swelling and amyloid-related imaging abnormalities (ARIA), which raise worries regarding patient risk tolerance. When making treatment decisions, finding a balance between possible advantages and safety concerns can be difficult.

Notable Recent Updates

• October 2022, to lower tau and amyloid beta in Alzheimer's disease patients, Cyclo Therapeutics, Inc. announced the start of its Phase 2b trial for Trappsol Cyclo. Approval for the Phase 2b trial has been given by the Institutional Review Board (IRB)
• September 2022, Esai Co., Ltd. and Biogen Inc. have released positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial. Lecanemab is an experimental anti-amyloid beta (Aβ) protofibril antibody used to treat mild Alzheimer's disease and mild cognitive impairment (MCI) caused by Alzheimer's disease

Healthcare Policies and Regulatory Landscape

The Food and Drug Administration (FDA) is principally in charge of regulatory authorities regarding Alzheimer's treatment medications in the United States (FDA). The FDA is essential in the assessment and approval of medications for a range of illnesses, including Alzheimer's disease. Manufacturers of medications for treating Alzheimer's disease must carry out thorough clinical studies to vouch for the security and effectiveness of their goods. When deciding whether to approve new medications, the FDA considers the data gathered from these trials. Pharmaceutical firms must follow the FDA's regulatory procedures to make sure their products fulfill the requirements for patient safety and efficacy.

Competitive Landscape

Key Players

• Eisai
• Biogen
• Roche
• Eli Lilly
• Merck & Co.
• Genentech
• AbbVie
• Johnson & Johnson
• Novartis
• Pfizer